Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2021-08-09 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2021-08-09 English
En relación con la Otra Información Relevante número 11105 del pasado 30 de julio de 2021, Grifols anuncia que ha recibido los consentimientos en relación con la Solicitud de Consentimiento.
Capital/Financing Update Classification · 99% confidence The document is a formal communication from Grifols, S.A. in Spanish, titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly references compliance with Article 227 of the Spanish Securities Market Act. The content details the successful receipt of consents from bondholders regarding modifications to their Senior Secured and Senior Unsecured Bonds to facilitate an internal corporate reorganization and the issuance/sale of Class B common stock in subsidiaries. This type of announcement, concerning debt restructuring, corporate actions related to financing, and subsequent legal/structural changes, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific, material financing/capital structure event.
2021-08-06 Spanish
FORM 6-K
Regulatory Filings
2021-07-30 English
FORM 6-K
Regulatory Filings
2021-07-30 English
Grifols anuncia que inicia un proceso de solicitud de consentimiento para modificar ciertas disposiciones de los documentos de emisión de sus Bonos.
Capital/Financing Update Classification · 98% confidence The document is a formal communication from Grifols, S.A., referencing Spanish securities law (artículo 227 del Texto Refundido de la Ley del Mercado de Valores) to announce 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content details the initiation of a consent solicitation process regarding modifications to the terms of its outstanding Senior Secured Bonds and Senior Unsecured Bonds. This action relates to corporate reorganization and the potential sale of shares in a subsidiary (Biomat USA). Since the document is announcing a specific corporate action related to debt instruments and capital structure changes, it aligns best with the 'Capital/Financing Update' category. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about financing terms modification.
2021-07-30 Spanish
FORM 6-K
Regulatory Filings
2021-07-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.